Coronavirus Notebook: Moderna Claims 94.5% Vaccine Efficacy, Janssen Starts Second ENSEMBLE Trial
The European Medicines Agency has begun a rolling review of Moderna’s mRNA vaccine, and its new executive director, Emer Cooke, has taken up her role with a promise to make tackling COVID-19 her “number one priority.”
You may also be interested in...
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
A new legislative proposal is seeking to empower the European Medicines Agency in tracking potential shortages of drugs and medical devices and enable the agency to play a greater role in coordinating clinical trials and vaccine research during health emergencies.
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.